Related Experiment Videos

Insulin pump therapy from the time of diagnosis of type 1 diabetes

Neesha Ramchandani1, Svetlana Ten, Henry Anhalt

  • 1Department of Pediatrics, Maimonides Medical Center/Infants and Children's Hospital of Brooklyn, Brooklyn, New York 11219, USA. nramchandani@maimonidesmed.org

Diabetes Technology & Therapeutics
|November 18, 2006
PubMed

Insights

Continuous subcutaneous insulin infusion (CSII) is a feasible and effective initial therapy for type 1 diabetes mellitus (T1DM), improving glycemic control and potentially extending the honeymoon period in newly diagnosed patients.

Area of Science:

  • Endocrinology
  • Metabolic Disorders
  • Pediatric Diabetes Management

Background:

  • Type 1 diabetes mellitus (T1DM) diagnosis presents a critical juncture for initiating insulin therapy.
  • Early intervention strategies aim to optimize glycemic control and preserve endogenous insulin production.

Purpose of the Study:

  • To evaluate the feasibility and efficacy of initiating continuous subcutaneous insulin infusion (CSII) within one month of T1DM diagnosis.
  • To assess the impact of early CSII on glycemic control, insulin requirements, and endogenous insulin secretion.

Main Methods:

  • Twenty-eight newly diagnosed T1DM patients (mean age 12.1 years) initiated CSII therapy, some within 24 hours of diagnosis.
  • Patients received CSII for up to three years, with high acceptance and adherence rates.
  • Key metrics included Hemoglobin A1c, C-peptide levels, insulin dosage, and weight changes.

Main Results:

  • Significant reduction in Hemoglobin A1c from 10.5% to 6.5%-7.4% within 18 months.
  • Stable endogenous insulin secretion (C-peptide) observed for the first 12 months.
  • No significant weight gain noted during the study period.

Conclusions:

  • CSII is a well-tolerated and effective initial insulin replacement therapy for newly diagnosed T1DM.
  • Early CSII demonstrates excellent clinical outcomes and may prolong the 'honeymoon period'.
  • Further randomized trials are needed to confirm superior preservation of endogenous insulin secretion and long-term complication reduction.
Abstract

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...